Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.71 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.66 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.61 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173273 | 1.00 | CYP19A1 (0.71) | CYP19A1HMOX1CYP51A1HMOX2 | |
| SCHEMBL11270111 | 0.91 | HMOX1 (0.76) | CYP19A1HMOX1CYP51A1 | |
| Denzimol SCHEMBL2110767 | 0.88 | CYP19A1 (0.65) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10932073 | 0.88 | CYP19A1 (0.73) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL11263221 | 0.87 | CYP19A1 (0.63) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6299490 | 0.85 | CYP19A1 (0.61) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL6301112 | 0.85 | CYP19A1 (0.61) | CYP19A1HMOX1CYP51A1 | |
| SCHEMBL10652258 | 0.84 | CYP19A1 (0.69) | CYP19A1HMOX2 | |
| SCHEMBL6981959 | 0.83 | CYP19A1 (0.73) | CYP19A1HMOX2 | |
| SCHEMBL7562437 | 0.83 | CYP19A1 (0.72) | CYP19A1HMOX1CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040063770-A1 | Method for treating Alzheimer's disease | WARNER-LAMBERT COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063770-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP19A1 203/4885HMOX1 367/4885CYP51A1 29/4885 |
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | CYP19A1 203/4885HMOX1 367/4885CYP51A1 29/4885 |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | CYP19A1 962/4885HMOX1 2641/4885CYP51A1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.